血液がん治療薬の世界市場レポート 2025年

血液がん治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年には年間平均成長率（CAGR）7.2％で1,068億米ドルに成長します。予測期間の成長は、疾患有病率の増加、新興市場、支持療法に起因すると考えられます。予測期間の主な動向には、研究開発投資、併用療法、バイオマーカー同定、免疫療法の進歩、個別化医療などが含まれます。

血液がん治療薬市場は、世界の死亡者数の増加と血液がん患者の有病率の上昇により成長を遂げています。リンパ腫、白血病、骨髄腫など、さまざまな血液がんには明確な危険因子があります。薬物療法によって管理または予防できるものもあれば、致命的な結果をもたらすものもあります。ブリストル・マイヤーズスクイブ社の報告書によると、2040年までに世界中で新たに185万人以上の血液がん患者が診断されると予測されています。これらの症例には、918,872例のリンパ腫、656,345例の白血病、275,047例の骨髄腫が含まれます。報告書はさらに、2040年までに世界中で約110万人が血液がんにより死亡すると推定しています。死亡者数の増加と血液がん患者の急増が、血液がん治療薬市場の成長を後押ししています。

血液がん治療薬市場で事業を展開する主要企業は、新薬の開発に注力し、競争優位に立つためにFDAの承認取得を目指しています。FDA承認とは、米国食品医薬品局（FDA）が医薬品を米国で合法的に上市・販売するための正式な認可を意味します。例えば、米国の製薬会社であるブリストル・マイヤーズスクイブは2024年3月、再発または難治性の慢性リンパ性白血病（CLL）または小リンパ球性リンパ腫（SLL）の成人患者を対象とした同社初で唯一のCAR T細胞療法についてFDAの承認を取得しました。この早期承認により、ブルトン型チロシンキナーゼ阻害剤とB細胞リンパ腫2阻害剤を含む少なくとも2種類の治療を受けたことのある患者への使用が認められます。TRANSCEND CLL 004試験に基づくと、Breyanziは20％の完全奏効率を示し、奏効者の奏効期間中央値は35.3カ月でした。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界血液がん治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の血液がん治療薬市場：成長率分析
• 世界の血液がん治療薬市場の実績：規模と成長, 2019-2024
• 世界の血液がん治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界血液がん治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の血液がん治療薬市場血液がんの種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 白血病
• リンパ腫
• 世界の血液がん治療薬市場薬物によって、実績と予測, 2019-2024, 2024-2029F, 2034F
• リツキサンまたはマブセラ（リツキシマブ）
• グリベックまたはグリベック（イマチニブ）
• レブラミド（レナリドミド）
• ベルケイド（ボルテゾミブ）
• タシグナ（ニロチニブ）
• ポマリスト（ポマリドミド）
• ビダザ（アザシチジン）
• カイプロリス（カルフィルゾミブ）
• アドセトリス（ブレンツキシマブベドチン）
• その他の薬物
• 世界の血液がん治療薬市場治療アプローチ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 主な調査結果
• 化学療法
• モノクローナル抗体/標的療法
• 免疫療法
• 世界の血液がん治療薬市場白血病の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 急性リンパ性白血病（ALL）
• 慢性リンパ性白血病（CLL）
• 急性骨髄性白血病（AML）
• 慢性骨髄性白血病（CML）
• その他の種類の白血病
• 世界の血液がん治療薬市場、リンパ腫別、タイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ホジキンリンパ腫
• 非ホジキンリンパ腫（NHL）
• バーキットリンパ腫
• 濾胞性リンパ腫
• マントル細胞リンパ腫
• その他の種類のリンパ腫

第7章 地域別・国別分析

• 世界の血液がん治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の血液がん治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 血液がん治療薬市場：競合情勢
• 血液がん治療薬市場：企業プロファイル
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Eli Lilly and Company Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Pfizer Inc.
• AbbVie Inc.
• Takeda Pharmaceutical Company Limited
• F. Hoffmann-La Roche Ltd.
• Bristol-Myers Squibb Company
• Astellas Pharma Inc.
• Roche Holding AG
• Merck & Co. Inc.
• Gilead Sciences Inc.
• Sanofi S.A.
• Eisai Co. Ltd.
• Jazz Pharmaceuticals plc
• Kyowa Kirin Co. Ltd.
• Menarini Group

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 血液がん治療薬市場2029：新たな機会を提供する国
• 血液がん治療薬市場2029：新たな機会を提供するセグメント
• 血液がん治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Blood cancer drugs are pharmaceutical treatments employed to combat blood cancer by harnessing the body's immune system to slow down the proliferation of cancer cells. These treatments encompass a range of modalities, including chemotherapy, biological therapy, targeted therapy, radiation therapy, and stem cell transplant, all tailored to address blood cancer effectively.

The primary categories of blood cancer drugs target leukemia and lymphoma. Leukemia pertains to a form of cancer affecting blood-forming tissues, particularly the bone marrow and lymphatic system. Various drug formulations are used in this context, including rituximab (Rituaxan/Mabthera), imatinib (Gleevec/Glivec), lenalidomide (Revlimid), bortezomib (Velcade), nilotinib (Tasigna), pomalidomide (Pomalyst), azacitidine (Fidanza), carfilzomib (Kyphosis), brentuximabvedotin (Adcetris), among others. These drugs are administered through diverse treatment approaches, spanning key findings, chemotherapeutic methods, monoclonal antibodies/targeted therapies, and immunotherapeutic interventions.

The blood cancer drugs market research report is one of a series of new reports from The Business Research Company that provides blood cancer drugs market statistics, including blood cancer drugs industry global market size, regional shares, competitors with a blood cancer drugs market share, detailed blood cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the blood cancer drugs industry. This blood cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The blood cancer drugs market size has grown strongly in recent years. It will grow from $74.78 billion in 2024 to $80.79 billion in 2025 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to advancements in research and development, aging population, increased awareness and early diagnosis, regulatory approvals.

The blood cancer drugs market size is expected to see strong growth in the next few years. It will grow to $106.8 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to increasing disease prevalence, emerging markets, supportive care. Major trends in the forecast period include research and development investments, combination therapies, biomarker identification, immunotherapy advancements, personalized medicine.

The blood cancer drugs market is experiencing growth due to the escalating number of deaths and the rising prevalence of blood cancer cases worldwide. Various forms of blood cancers, including lymphoma, leukemia, myeloma, and others, have distinct risk factors. Some can be managed or prevented through drug therapies, while others may result in fatalities. According to a report by Bristol-Myers Squibb Company, it is projected that by 2040, over 1.85 million new blood cancer cases will be diagnosed globally. These cases will include 918,872 instances of lymphoma, 656,345 of leukemia, and 275,047 of myeloma. The report further estimates that by 2040, around 1,100,000 deaths will occur worldwide due to blood cancer. The increasing number of deaths and the surging incidence of blood cancer cases are propelling the growth of the blood cancer drug market.

Major companies operating in the blood cancer drugs market are focusing on developing new drugs and seeking FDA approval to gain a competitive edge. FDA approval refers to the formal authorization granted by the United States Food and Drug Administration (FDA) for a pharmaceutical product to be legally marketed and sold in the U.S. For example, in March 2024, Bristol Myers Squibb, a US-based pharmaceutical company, received FDA approval for its first and only CAR T-cell therapy for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This accelerated approval allows its use in patients who have previously received at least two treatments, including a Bruton tyrosine kinase inhibitor and a B-cell lymphoma 2 inhibitor. Based on the TRANSCEND CLL 004 trial, Breyanzi showed a 20% complete response rate and a median duration of response of 35.3 months among responders.

Major players in the blood cancer drugs market are actively engaged in the development of novel drugs and pursuing FDA approval to gain a competitive edge in the industry. FDA approval for drugs is the formal authorization issued by the United States Food and Drug Administration (FDA) for the legal marketing and sale of a pharmaceutical product in the United States. These approvals hold immense value in the market. In May 2023, the FDA granted its approval to Epcoritamab, commercially known as Epkinly, for the treatment of diffuse large B-cell lymphoma (DLBCL) in patients who have undergone at least two prior lines of systemic therapy. Epkinly, classified as a CD20xCD3 T-cell engager, exhibited significant efficacy during clinical trials, with a 61% tumor shrinkage rate in patients who had previously received multiple treatments. This approval serves as a noteworthy addition to the available treatment options for DLBCL.

In July 2022, GSK, a prominent pharmaceutical company based in the UK, completed the acquisition of Sierra Oncology for an undisclosed sum. This strategic acquisition bolsters GSK's oncology portfolio. Sierra Oncology, headquartered in the United States, specializes in the development of cancer drugs, including treatments for blood cancers.

Major companies operating in the blood cancer drugs market include Amgen Inc., AstraZeneca PLC, Bayer AG, Eli Lilly and Company Inc., Johnson & Johnson, Novartis AG, Pfizer Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Astellas Pharma Inc., Roche Holding AG, Merck & Co. Inc., Gilead Sciences Inc., Sanofi S.A., Eisai Co. Ltd., Jazz Pharmaceuticals PLC, Kyowa Kirin Co. Ltd., Menarini Group, Millennium Pharmaceuticals Inc., Mundipharma International Limited, Mylan N.V., Ono Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Pharmacyclics LLC, Regeneron Pharmaceuticals Inc., Seattle Genetics Inc., Servier Laboratories, Shire PLC, Spectrum Pharmaceuticals Inc., Taiho Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Tolero Pharmaceuticals Inc., UCB S.A., Vertex Pharmaceuticals Incorporated

North America was the largest region in the blood cancer drugs market in 2024. Middle East is expected to be the fastest-growing region in the blood cancer drugs market during the forecast period. The regions covered in the blood cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the blood cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The blood cancer drugs market consists of sales Altretamine, Bendamustine, Bendamustine, and Carboplatin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Blood Cancer Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on blood cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for blood cancer drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The blood cancer drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Blood Cancer Type: Leukemia; Lymphoma
• 2) By Drugs: Rituxan Or Mabthera (Rituximab); Gleevec Or Glivec (Imatinib); Revlimid (Lenalidomide); Velcade (Bortezomib); Tasigna (Nilotinib); Pomalyst (Pomalidomide); Vidaza (Azacitidine); Kyprolis (Carfilzomib); Adcetris (Brentuximab Vedotin); Other Drugs
• 3) By Treatment Approaches: Key Findings; Chemotherapeutic; MAbs/Targeted Therapies; Immunotherapeutic
• Subsegments:
• 1) By Leukemia: Acute Lymphoblastic Leukemia (ALL); Chronic Lymphocytic Leukemia (CLL); Acute Myeloid Leukemia (AML); Chronic Myeloid Leukemia (CML); Other Types of Leukemia
• 2) By Lymphoma: Hodgkin Lymphoma; Non-Hodgkin Lymphoma (NHL); Burkitt Lymphoma; Follicular Lymphoma; Mantle Cell Lymphoma; Other Types of Lymphoma
• Companies Mentioned: Amgen Inc.; AstraZeneca PLC; Bayer AG; Eli Lilly and Company Inc.; Johnson & Johnson
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Blood Cancer Drugs Market Characteristics

3. Blood Cancer Drugs Market Trends And Strategies

4. Blood Cancer Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Blood Cancer Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Blood Cancer Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Blood Cancer Drugs Market Growth Rate Analysis
• 5.4. Global Blood Cancer Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Blood Cancer Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Blood Cancer Drugs Total Addressable Market (TAM)

6. Blood Cancer Drugs Market Segmentation

• 6.1. Global Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Leukemia
• Lymphoma
• 6.2. Global Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rituxan Or Mabthera (Rituximab)
• Gleevec Or Glivec (Imatinib)
• Revlimid (Lenalidomide)
• Velcade (Bortezomib)
• Tasigna (Nilotinib)
• Pomalyst (Pomalidomide)
• Vidaza (Azacitidine)
• Kyprolis (Carfilzomib)
• Adcetris (Brentuximab Vedotin)
• Other Drugs
• 6.3. Global Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Key Findings
• Chemotherapeutic
• MAbs/Targeted Therapies
• Immunotherapeutic
• 6.4. Global Blood Cancer Drugs Market, Sub-Segmentation Of Leukemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Lymphoblastic Leukemia (ALL)
• Chronic Lymphocytic Leukemia (CLL)
• Acute Myeloid Leukemia (AML)
• Chronic Myeloid Leukemia (CML)
• Other Types of Leukemia
• 6.5. Global Blood Cancer Drugs Market, Sub-Segmentation Of By Lymphoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hodgkin Lymphoma
• Non-Hodgkin Lymphoma (NHL)
• Burkitt Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Other Types of Lymphoma

7. Blood Cancer Drugs Market Regional And Country Analysis

• 7.1. Global Blood Cancer Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Blood Cancer Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Blood Cancer Drugs Market

• 8.1. Asia-Pacific Blood Cancer Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Blood Cancer Drugs Market

• 9.1. China Blood Cancer Drugs Market Overview
• 9.2. China Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Blood Cancer Drugs Market

• 10.1. India Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Blood Cancer Drugs Market

• 11.1. Japan Blood Cancer Drugs Market Overview
• 11.2. Japan Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Blood Cancer Drugs Market

• 12.1. Australia Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Blood Cancer Drugs Market

• 13.1. Indonesia Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Blood Cancer Drugs Market

• 14.1. South Korea Blood Cancer Drugs Market Overview
• 14.2. South Korea Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Blood Cancer Drugs Market

• 15.1. Western Europe Blood Cancer Drugs Market Overview
• 15.2. Western Europe Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Blood Cancer Drugs Market

• 16.1. UK Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Blood Cancer Drugs Market

• 17.1. Germany Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Blood Cancer Drugs Market

• 18.1. France Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Blood Cancer Drugs Market

• 19.1. Italy Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Blood Cancer Drugs Market

• 20.1. Spain Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Blood Cancer Drugs Market

• 21.1. Eastern Europe Blood Cancer Drugs Market Overview
• 21.2. Eastern Europe Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Blood Cancer Drugs Market

• 22.1. Russia Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Blood Cancer Drugs Market

• 23.1. North America Blood Cancer Drugs Market Overview
• 23.2. North America Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Blood Cancer Drugs Market

• 24.1. USA Blood Cancer Drugs Market Overview
• 24.2. USA Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Blood Cancer Drugs Market

• 25.1. Canada Blood Cancer Drugs Market Overview
• 25.2. Canada Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Blood Cancer Drugs Market

• 26.1. South America Blood Cancer Drugs Market Overview
• 26.2. South America Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Blood Cancer Drugs Market

• 27.1. Brazil Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Blood Cancer Drugs Market

• 28.1. Middle East Blood Cancer Drugs Market Overview
• 28.2. Middle East Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Blood Cancer Drugs Market

• 29.1. Africa Blood Cancer Drugs Market Overview
• 29.2. Africa Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Blood Cancer Drugs Market Competitive Landscape And Company Profiles

• 30.1. Blood Cancer Drugs Market Competitive Landscape
• 30.2. Blood Cancer Drugs Market Company Profiles
  • 30.2.1. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Eli Lilly and Company Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis

31. Blood Cancer Drugs Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Pfizer Inc.
• 31.3. AbbVie Inc.
• 31.4. Takeda Pharmaceutical Company Limited
• 31.5. F. Hoffmann-La Roche Ltd.
• 31.6. Bristol-Myers Squibb Company
• 31.7. Astellas Pharma Inc.
• 31.8. Roche Holding AG
• 31.9. Merck & Co. Inc.
• 31.10. Gilead Sciences Inc.
• 31.11. Sanofi S.A.
• 31.12. Eisai Co. Ltd.
• 31.13. Jazz Pharmaceuticals plc
• 31.14. Kyowa Kirin Co. Ltd.
• 31.15. Menarini Group

32. Global Blood Cancer Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Blood Cancer Drugs Market

34. Recent Developments In The Blood Cancer Drugs Market

35. Blood Cancer Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Blood Cancer Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Blood Cancer Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Blood Cancer Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer